Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis

Sonalie Patel*, Michelle T. Martin, Steven L. Flamm

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
JournalLiver International
DOIs
StateAccepted/In press - 2021

Keywords

  • cirrhosis
  • decompensated
  • direct-acting antivirals
  • hepatitis C virus
  • retreatment
  • salvage therapy
  • sofosbuvir
  • velpatasvir
  • voxilaprevir

ASJC Scopus subject areas

  • Hepatology

Cite this